<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50215">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832129</url>
  </required_header>
  <id_info>
    <org_study_id>PCRG_VB12_CM</org_study_id>
    <nct_id>NCT01832129</nct_id>
  </id_info>
  <brief_title>Vitamin B12 Acceptance and Biomarker Response Study</brief_title>
  <official_title>Acceptance and Biomarker Response With Oral vs. Intramuscular Supplementation of Vitamin B12 in Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Care Research Group, University of Basel (Sponsor-Investigator)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarelab, Clinical Laboratory, Olten, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, biomarker response after supplementation with oral and intramuscular vitamin
      B12 will be compared in a randomized clinical trial. Electronic compliance monitoring will
      be used to control for non compliance as a possible confounder in oral treatment.
      Additionally subjective acceptance in terms of presumed preferences will be compared with
      oral vs. intramuscular supplementation of vitamin B12 in the view of the patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Biochemical response to vitamin B12 substitution</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vitamin B12 associated biomarkers (Vitamin B12, Holotranscobolamin, Homocystein, MCV, hypersegmentated neutrophils)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>taking and timing adherence with oral vitamin B12</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adherence to oral vitamin B12 supplementation will be measured with an electronic adherence monitoring device. The number of doses taken (taking adherence) and the number of doses taken within the defined time-frame (timing adherence) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient acceptance of oral vs. i.m. vitamin B12 supplementation</measure>
    <time_frame>day 0, day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acceptance of the two routes of administration of vitamin B12 substitution by the patients will be measured by specific questionnaires before and after exposure to the medication in both arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vitamin B 12 Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin B12 i.m.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin B12 oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral administration of vitamin B12</intervention_name>
    <description>Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.</description>
    <arm_group_label>Vitamin B12 oral</arm_group_label>
    <other_name>Cyanocobolamin</other_name>
    <other_name>B12 &quot;Ankermann&quot; 1 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>i.m. injection of vitamin B12</intervention_name>
    <description>Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.</description>
    <arm_group_label>Vitamin B12 i.m.</arm_group_label>
    <other_name>Vitamin B12 intramuscular</other_name>
    <other_name>Cyanocobolamin</other_name>
    <other_name>Vitarubin Depot</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General practitioner's prescription for Vitamin B12 deficiency testing

          -  Age&gt; 18 years

          -  Ability to give written informed consent

          -  Vitamin B12 serum concentrations &lt; 200pmol/l

          -  indication for vitamin B12 supplementation according to the General
             practitioners estimation

        Exclusion Criteria:

          -  Patients with incorrect intake of vitamin preparations containing vitamin B12

          -  Patients with previously diagnosed dementia

          -  Patients with known hereditary transcobalamin transportation defects

          -  lack of written and/or oral understanding in German, French, Italian or English
             languages
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt E Hersberger, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmaceutical Care Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyrill Jeger, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Philipp N Walter, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Pharmaceutical Care Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corina Metaxas</last_name>
    <email>corina.metaxas@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Walter</last_name>
    <email>philipp.walter@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pharmaceutical Care Research Group</name>
      <address>
        <city>Basel</city>
        <zip>CH-4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corina Metaxas</last_name>
      <phone>+41 79 548 47 28</phone>
      <email>corina.metaxas@unibas.ch</email>
    </contact>
    <contact_backup>
      <last_name>Philipp Walter</last_name>
      <email>philipp.walter@unibas.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Cyrill Jeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Walter, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://pharma.unibas.ch/research-groups/details/home/group/pharmaceuticalcare/</url>
    <description>Pharmaceutical Care Research Group, University of Basel</description>
  </link>
  <link>
    <url>http://www.aarelab.ch</url>
    <description>Study site</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Philipp Walter, PhD</investigator_full_name>
    <investigator_title>Msc</investigator_title>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
